Sol-Gel Technologies Basic EPS 2016-2024 | SLGL
Sol-Gel Technologies basic eps from 2016 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
| Sol-Gel Technologies Annual Basic EPS |
| 2023 |
$-1.01 |
| 2022 |
$-0.65 |
| 2021 |
$0.14 |
| 2020 |
$-1.30 |
| 2019 |
$-1.26 |
| 2018 |
$-1.80 |
| 2017 |
$-5.02 |
| 2016 |
$-3.30 |
| 2015 |
$-1.53 |
| Sol-Gel Technologies Quarterly Basic EPS |
| 2024-06-30 |
$0.07 |
| 2024-03-31 |
$-0.23 |
| 2023-12-31 |
$-0.15 |
| 2023-09-30 |
$-0.21 |
| 2023-06-30 |
$-0.22 |
| 2023-03-31 |
$-0.43 |
| 2022-12-31 |
$-0.25 |
| 2022-09-30 |
$-0.15 |
| 2022-06-30 |
$-0.01 |
| 2022-03-31 |
$-0.24 |
| 2021-12-31 |
$0.61 |
| 2021-09-30 |
$0.06 |
| 2021-06-30 |
$-0.35 |
| 2021-03-31 |
$-0.18 |
| 2020-12-31 |
$-0.29 |
| 2020-09-30 |
$-0.37 |
| 2020-06-30 |
$-0.31 |
| 2020-03-31 |
$-0.33 |
| 2019-12-31 |
$-0.33 |
| 2019-09-30 |
$-0.37 |
| 2019-06-30 |
$-0.26 |
| 2019-03-31 |
$-0.30 |
| 2018-12-31 |
$-0.65 |
| 2018-09-30 |
$-0.40 |
| 2018-06-30 |
$-0.36 |
| 2018-03-31 |
$-0.39 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
$-0.98 |
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.015B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
